Validation of miR-31-3p Expression to Predict Cetuximab Efficacy When Used as First-Line Treatment in
Adolescent
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
/ administration & dosage
Bevacizumab
/ administration & dosage
Biomarkers, Tumor
/ genetics
Camptothecin
/ administration & dosage
Cetuximab
/ administration & dosage
Colorectal Neoplasms
/ drug therapy
ErbB Receptors
/ genetics
Fluorouracil
/ administration & dosage
Gene Expression Regulation, Neoplastic
/ drug effects
Humans
Kaplan-Meier Estimate
Leucovorin
/ administration & dosage
MicroRNAs
/ genetics
Middle Aged
Neoplasm Metastasis
Progression-Free Survival
Young Adult
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
01 01 2019
01 01 2019
Historique:
received:
07
05
2018
revised:
02
07
2018
accepted:
09
08
2018
pubmed:
16
8
2018
medline:
27
2
2020
entrez:
16
8
2018
Statut:
ppublish
Résumé
MiR-31-3p expression has been shown to be associated with response to anti-EGFR therapy. We investigated the predictive role of this biomarker in the FIRE-3 study population, including its ability to differentiate outcomes between patients receiving anti-EGFR and anti-VEGF therapy. MiR-31-3p expression was measured in primary tumors obtained from 340 patients with Low miR-31-3p expressers benefited from cetuximab compared with bevacizumab for PFS [HR, 0.74; 95% confidence interval (CI), 0.55-1.00; MiR-31-3p expression level was validated as a predictive biomarker of cetuximab therapy efficacy for patients with
Identifiants
pubmed: 30108104
pii: 1078-0432.CCR-18-1324
doi: 10.1158/1078-0432.CCR-18-1324
doi:
Substances chimiques
Biomarkers, Tumor
0
MIRN31 microRNA, human
0
MicroRNAs
0
Bevacizumab
2S9ZZM9Q9V
EGFR protein, human
EC 2.7.10.1
ErbB Receptors
EC 2.7.10.1
Cetuximab
PQX0D8J21J
Leucovorin
Q573I9DVLP
Fluorouracil
U3P01618RT
Camptothecin
XT3Z54Z28A
Types de publication
Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
134-141Informations de copyright
©2018 American Association for Cancer Research.